Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 04, 2015 1:38 AM ET

Pharmaceuticals

Company Overview of Phosphate Therapeutics Ltd.

Company Overview

Phosphate Therapeutics Ltd. operates as a pharmaceutical company. The company engages in development of drug named PT20 to cure high phosphate levels in blood. Phosphate Therapeutics Ltd. was founded in 2011 and is based in London, United Kingdom. The company operates as a subsidiary of Shield Therapeutics.

London,  

United Kingdom

Founded in 2011

Key Executives for Phosphate Therapeutics Ltd.

Chief Executive Officer
Compensation as of Fiscal Year 2015.

Phosphate Therapeutics Ltd. Key Developments

Phosphate Therapeutics Limited Announces Positive Results in the PEACH Pivotal Study of its Novel Phosphate Binder (PT20) for the Treatment of hyperphosphataemia

Phosphate Therapeutics Limited announced positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD). PT20, invented in the UK by leading Cambridge-based scientists and exclusively licensed by Phosphate Therapeutics, is a novel phosphate binder that is based on proprietary 'Interstitial Mineral Hydroxide' technology that uses adipate-doped iron oxide at the core of the product, thereby allowing PT20 to act as a very high capacity 'phosphate sponge'. This first pivotal study of PT20 in approximately 150 subjects with hyperphosphataemia related to DD-CKD, clearly met its primary endpoint (p<0.0001) demonstrating that PT20 successfully lowered serum phosphate levels compared to placebo, whilst all secondary analyses of the primary endpoint were also statistically significant (p<0.01). All of the study's PT20 dose groups showed a phosphate reduction at day 28 compared to baseline and this reduction was dose-related. PT20 was very well tolerated with less than 5% of the patients who received study medication withdrawing because of adverse events; and no Serious Adverse Events were considered related to study medication. The PEACH study (A Pharmacodynamic Evaluation of Adipate modified iron in subjects with Chronic kidney disease and Hyperphosphataemia) was a pivotal Phase 2b, multi-centre, placebo-controlled, randomised study of a wide range of doses of PT20 in dialysis dependent subjects with hyperphosphataemia. The results from this study will help define the treatment regimen that will be taken forward into the phase 3 study of PT20 in dialysis dependent patients. The data from these two studies are then expected to form the basis for new drug applications to the FDA and other Health Authorities for the approval of PT20 in the control of hyperphosphataemia, initially in patients dependent on dialysis.

Phosphate Therapeutics Announces Completion of Subject Recruitment into the Peach Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia

Phosphate Therapeutics announced that recruitment of subjects into PEACH, the first pivotal trial of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD), has completed as the pre-specified number of randomisations has been achieved. PT20, invented by UK-based scientists from the Medical Research Council and exclusively licensed by Phosphate Therapeutics, is a novel phosphate binder that is based on proprietary 'Interstitial Mineral Hydroxide' (IMH) technology that uses adipate-doped iron oxide at the core of the product, thereby allowing PT20 to act as a very high capacity 'phosphate sponge'. Data from early in vitro and in vivo studies on PT20 suggests it exhibits significant higher specificity and efficacy than phosphate binders. The PEACH study (A Pharmacodynamic Evaluation of Adipate modified iron in subjects with Chronic kidney disease and Hyperphosphataemia) is a Phase 2b, multi-centre, placebo-controlled, randomised study of PT20 in subjects who are dialysis dependent with hyperphosphataemia. A range of doses of PT20 are being tested for effect on phosphate levels in the blood. This study is being conducted in more than 20 expert nephrology centres in the USA, with Dr. Geoff Block as the Principal Investigator. Dr. Block is a widely published and world-recognised clinical expert in the field of kidney disease and mineral metabolism disorders and is Adjunct Professor of Medicine at University of Colorado as well as Director of Clinical Research at Denver Nephrology. The results, expected in the second quarter of 2015, will help define the doses and regimen that will be taken forward into the second pivotal study of PT20 in dialysis dependent patients. The data from these two studies are then expected to form the basis for new drug applications to the FDA and other Health Authorities for the approval of PT20 in the control of hyperphosphataemia in patients dependent on dialysis.

Similar Private Companies By Industry

Company Name Region
Ferring Pharmaceuticals Ltd. Europe
Lilly Research Centre Limited Europe
Zogenix Europe Limited Europe
Galderma (U.K.) Ltd. Europe
Pharminox Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Phosphate Therapeutics Ltd., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.